Literature DB >> 2549483

Ocular manifestations of acquired immune deficiency syndrome.

D A Jabs1, W R Green, R Fox, B F Polk, J G Bartlett.   

Abstract

The ocular complications of acquired immune deficiency syndrome (AIDS) include: (1) a noninfectious microangiopathy, most often seen in the retina, consisting of cotton-wool spots with or without intraretinal hemorrhages and other microvascular abnormalities; (2) opportunistic ocular infections, primarily cytomegalovirus (CMV) retinitis; (3) conjunctival, eyelid, or orbital involvement by those neoplasms seen in patients with AIDS (i.e., Kaposi's sarcoma and lymphoma); and (4) neuro-ophthalmic lesions. In a series of 200 AIDS patients evaluated clinically, AIDS retinopathy was present in 66.5%. Sixty-four percent had cotton-wool spots, and 12% had intraretinal hemorrhages. Cytomegalovirus retinitis was diagnosed in 28% of AIDS patients. Neuro-ophthalmic lesions were found in 8% of all AIDS patients and were present in 33% of those patients with cryptococcal meningitis. Acquired immune deficiency syndrome retinopathy was present in 40% of 35 patients with the AIDS-related complex (ARC) and in 1.3% of 232 patients with asymptomatic human immunodeficiency virus (HIV) infection, evaluated photographically. These results suggest that the prevalence of AIDS retinopathy increases with increasing severity of HIV infection, and that CMV retinitis presents a significant vision-threatening problem in AIDS patients.

Entities:  

Mesh:

Year:  1989        PMID: 2549483     DOI: 10.1016/s0161-6420(89)32794-1

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  47 in total

Review 1.  Changing patterns of HIV related ocular disease.

Authors:  S Rauz; P I Murray
Journal:  Sex Transm Infect       Date:  1999-02       Impact factor: 3.519

2.  Latent ocular deviations in patients with advanced AIDS.

Authors:  E España-Gregori; R Montés-Micó; I Bueno-Gimeno; M Díaz-Llopi; J L Menezo-Rozalén
Journal:  Doc Ophthalmol       Date:  2001-11       Impact factor: 2.379

Review 3.  Ophthalmic manifestations of immunodeficiency states.

Authors:  R Rescigno; M Dinowitz
Journal:  Clin Rev Allergy Immunol       Date:  2001-04       Impact factor: 8.667

Review 4.  Ocular and systemic causes of retinopathy in patients without diabetes mellitus.

Authors:  Jayant Venkatramani; Paul Mitchell
Journal:  BMJ       Date:  2004-03-13

Review 5.  Understanding the role of aldose reductase in ocular inflammation.

Authors:  U C S Yadav; S K Srivastava; K V Ramana
Journal:  Curr Mol Med       Date:  2010-08       Impact factor: 2.222

6.  Neuro-ophthalmological disorders in HIV infected subjects with neurological manifestations.

Authors:  J-C Mwanza; L K Nyamabo; T Tylleskär; G T Plant
Journal:  Br J Ophthalmol       Date:  2004-11       Impact factor: 4.638

7.  Combination of ganciclovir and granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. The ACTG 073 Team.

Authors:  D Hardy; S Spector; B Polsky; C Crumpacker; C van der Horst; G Holland; W Freeman; M H Heinemann; G Sharuk; J Klystra
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994       Impact factor: 3.267

8.  Immune predispositions for cytomegalovirus retinitis in AIDS. The HNRC Group.

Authors:  R D Schrier; W R Freeman; C A Wiley; J A McCutchan
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

9.  Induction of cystine-glutamate transporter xc- by human immunodeficiency virus type 1 transactivator protein tat in retinal pigment epithelium.

Authors:  Christy C Bridges; Huankai Hu; Seiji Miyauchi; Umapathy N Siddaramappa; Malliga E Ganapathy; Leszek Ignatowicz; Dennis M Maddox; Sylvia B Smith; Vadivel Ganapathy
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-09       Impact factor: 4.799

Review 10.  Current perspectives on ophthalmic mycoses.

Authors:  Philip A Thomas
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.